

# Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure committee meeting 1

**Date:** 9/5/2024

**Location:** Wandle 41+40, NICE offices, 2nd floor, 2 Redman Place, London

E20 1JQ and via Zoom

Minutes: Final

Committee members present:	
Abdallah Al-Mohammad	Present via Zoom
Nigel Beckett	Present in person
Gayle Campbell	Present in person
Hugh Gallagher	Present via Zoom
Joseph Mills (Chair)	Present in person
Richard Mindham	Present in person
Susan Piper (Topic Advisor)	Present in person
Chakravarthi Rajkumar	Present via Zoom
Delyth Rucarean	Present in person
Duwarakan Satchithananda	Present via Zoom
Louis Savage	Present in person
Eduard Shantsila	Present in person
Clare Taylor	Present via Zoom
Colin Wilkinson	Present via Zoom

In attendance:		
Annette Chalker	Technical Analyst	Present in person
Catrina Charlton	Guideline Commissioning Manager	Present in person
Jemma Deane	Senior Information Specialist	Present in person
Kirsty Luckham	Health Economist	Present via Zoom
Lisa Miles	Technical Analyst	Present via Zoom
Sade Naku	Health Economist	Present in person
Eleanor Samarasekera	Senior Technical Analyst	Present in person
Daniel Smithson	Technical Analyst, QS&I	Present via Zoom

Sharon Swain	Associate Director/Guideline Lead	Present in person
Amelia Unsworth	Senior Project Manager	Present in person
David Wonderling	Senior Health Economics Adviser	Present in person

Observers:	
Emily Herrett	INTEGRATE study
Frederick Martineau	INTEGRATE study
Laurie Tomlinson	INTEGRATE study

Apologies:	
Alan Thomas	Lay member
Joanna Perkin	NICE Editor

# 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 1st meeting on the update of the pharmacological management of chronic heart failure.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: discussion of the evidence for the pharmacological management of chronic heart failure with reduced ejection fraction and the considerations for a health economic model.

### 2. Confirmation of matters under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were:

 pharmacological management of chronic heart failure with reduced ejection fraction in adults.

The Chair and a senior member of the technical team reviewed the declarations of interest register for interests previously declared and noted that none posed a conflict with the matters under discussion, therefore no further action was required.

The Chair asked everyone to verbally declare any interests in addition to those previously declared.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Nigel Beckett	Consultant Physician in Ageing and Health, Guys and St Thomas' NHS Foundation Trust	I have become a member of the Steering Group for a Renal Cardiometabolic project that is running in Lambeth in South-East London (SEL). This is part of a larger piece of work looking at improving Multimorbidity Model of Care across the whole of SEL.  I receive no financial support in regard to this, 9 May 2024.	Direct Non- Financial Professional and Personal	Non- specific Declare and Participate No action needed other than process of open declaration
Susan Piper	Cardiology Consultant, King's College Hospital, London	I remain past chair of the British Society for Heart Failure (BSH) education committee, 9 May 2024.	Direct Non- Financial professional and personal	Specific Declare and Participate No action needed other than process of open declaration
Susan Piper	Cardiology Consultant, King's College Hospital, London	I am giving a talk on 5 June 2024 on the British Society for Heart Failure (BSH) "25 in 25" at the British Cardiovascular Society. I am not getting paid for this but the BSH is paying for travel and one night's accommodation, 9 May 2024	Direct Non- Financial professional and personal Direct Financial	Specific Declare and participate No action needed other than process of open declaration - Reasonable expenses

Duwarakan Satchithananda	Community Heart Failure Consultant Cardiologist, Midlands Partnership Foundation Trust	Grantholder of 2 grants from NHS England about improving and personalising heart failure education for heart failure patients. They are grants held by the Stokeon-Trent and Staffordshire Intermediate Care Board, 9 May 2024.	Direct Non- Financial Professional and Personal Indirect Financial	Non- specific Declare and Participate No action needed other than process of open declaration
Duwarakan Satchithananda	Community Heart Failure Consultant Cardiologist, Midlands Partnership Foundation Trust	I have also spoken at GP, cardiology registrar and nurse education meetings to promote the relaunch of the community heart failure service. The meetings themselves have been sponsored through pharma companies (Novartis and Pfizer), 9 May 2024.	Direct Non- Financial Professional and Personal	Non- specific Declare and Participate No action needed other than process of open declaration
Louis Savage	General Practitioner, Stroud General (Community) Hospital, Gloucestershire Royal Hospital & Cotswold Medical Practice	Member, British Geriatrics Society working group on Physician Assisted Suicide	Direct Non- Financial Professional and Personal	Non- specific Declare and Participate No action needed other than process of open declaration

The Chair and a senior member of the technical team noted that none posed a conflict with the matters under discussion, therefore no further action was required.

### 3. Draft scope

The Committee discussed the draft scope and plans for publication.

# 4. Evidence review: Pharmacological management of chronic heart failure with reduced ejection fraction

The Committee discussed the evidence for the pharmacological management of chronic heart failure with reduced ejection fraction.

# 5. Health economic model

The Committee discussed the considerations for a health economic model on the pharmacological management of chronic heart failure with reduced ejection fraction.

### 6. Network meta-analysis

The Committee discussed the considerations for a network meta-analysis.

### 7. Any other business

None

**Date of next meeting:** Thursday 20 June 2024, 1000-1200

Location of next meeting: Virtual via Zoom